Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel crystalline forms of anticancer compound CX1409 and preparation method and application of novel crystalline forms of anticancer compound CX1409

A technology of CX1409 and compound, which is applied in the field of two new crystal forms of anticancer compound CX1409 and its preparation, can solve problems such as no crystal form, and achieve the effect of simple preparation method, good yield and high purity

Inactive Publication Date: 2018-01-05
BEIJING KONRUNS PHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The above-mentioned anticancer compound CX1409 is known to be used in anticancer, but so far, there is no relevant research on the crystal form

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel crystalline forms of anticancer compound CX1409 and preparation method and application of novel crystalline forms of anticancer compound CX1409
  • Novel crystalline forms of anticancer compound CX1409 and preparation method and application of novel crystalline forms of anticancer compound CX1409
  • Novel crystalline forms of anticancer compound CX1409 and preparation method and application of novel crystalline forms of anticancer compound CX1409

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1: the preparation of CX1409 crude product

[0055] The preparation of CX1409 crude product specifically comprises the following steps:

[0056] (1) Dissolve CX1409-01 (15g) in DMF (45mL), then add imidazole (5.22g), control the temperature at about 20-25°C while stirring, slowly add TESCl (6.74g), dropwise, 20 Stir at ~25°C for 0.5h. After the reaction was complete, purified water (105 mL) and DCM (150 mL) were added to separate the layers. The organic phase was washed with water (105 mL) and saturated NaCl (75 mL). The liquid was separated, and the organic phase was evaporated to dryness to obtain the crude product. Add n-hexane (150 mL) and EA (15 mL) to the crude product, stir at room temperature for 1 h, filter with suction, wash the filter cake with a small amount of n-hexane, and vacuum-dry at 40°C for 2 h to obtain 16.7 g of the product CX1409-05.

[0057] (2) Under the protection of nitrogen, control the temperature at -30°C, add NaHMDS (1.0M in ...

Embodiment 2

[0062] Example 2: Preparation of CX1409 Form A

[0063] Weigh 1.0 g of crude CX1409 (prepared in Example 1) and add it to 5 mL of ethanol, stir for 10 min, then add 6 mL of ethanol, heat to 55 ° C to dissolve until clear, and keep for 45 min; slowly drop the clear solution into Stir in 9mL of 55°C water at low speed, slowly cool down to 30°C (cooling rate: 0.5°C / min), grow crystals at constant temperature for 60 minutes, then continue to slowly cool down to 20°C (cooling rate: 0.3°C / min), grow crystals for 120 minutes The resulting crystals were collected by filtration and dried at 40° C. for 16 h under vacuum to obtain 684 mg of Form A (purity: 99.63%). The powder X-ray diffraction pattern is shown in image 3 .

Embodiment 3

[0064] Example 3: Preparation of CX1409 Form A

[0065] Weigh 1.0 g of CX1409 crude product (prepared in Example 1) and add it to 10 mL of ethanol, heat to 50 ° C to dissolve until clear, and keep for 30 min; slowly drop the clear solution into 9 mL of 50 ° C water, stir at a low speed , slowly cool down to 25°C (cooling rate is 0.5°C / min), grow crystals at constant temperature for 40 minutes, then continue to slowly cool down to 15°C (cooling rate is 0.3°C / min), grow crystals for 90 minutes; the obtained crystals are collected by filtration, and in Drying at 40°C for 16 h under vacuum conditions yielded 696 mg of Form A (purity: 99.87%), and its powder X-ray diffraction pattern is shown in image 3 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of compounds, in particular to two novel crystalline forms of an anticancer compound CX1409. A crystalline form A of the anticancer compound CX1409 is determined byusing a powder X-ray diffraction method, wherein characteristic diffraction peaks are shown at 4.3 degree, 8.7 degree, 11.0 degree, 12.5 degree, 13.0 degree, 14.1 degree, 15.4 degree, 17.4 degree, 18.4 degree, 19.6 degree, 20.1 degree, 20.8 degree, 21.7 degree, 27.0 degree, 29.0 degree, 30.6 degree and 31.4 degree in an X-ray powder diffraction spectrum expressed by a diffraction angle of 2 theta+ / -0.3 degree; a crystalline form B of the anticancer compound CX1409 is determined by using the powder X-ray diffraction method, wherein characteristic diffraction peaks are shown at 4.9 degree, 5.4degree, 5.8 degree, 6.4 degree, 8.0 degree, 9.4 degree and 12.9 degree in an X-ray powder diffraction spectrum expressed by a diffraction angle of 2 theta + / -0.3 degree. The above two crystalline forms are not reported, outlines of the two crystalline forms are clear, and the two crystalline forms can be perfectly reproduced; besides, the two crystalline forms have the advantages of being good instability of preparation and high in yield and purity, can be applied to anti-tumor drugs, and have wide application prospects.

Description

technical field [0001] The invention relates to compound crystals, in particular to two new crystal forms of the anticancer compound CX1409 and its preparation method and application. Background technique [0002] Since the US FDA approved paclitaxel for the treatment of ovarian cancer in 1993, paclitaxel and its derivatives have been widely used in breast cancer, non-small cell lung cancer, head and neck tumors, gastric cancer, and prostate cancer. Among the current anticancer drugs, paclitaxel is a class of anticancer drugs with the widest therapeutic effect, the lowest toxicity and the highest curative effect. [0003] Currently, there are 3 paclitaxel drugs approved for use worldwide, they are paclitaxel, docetaxel and cabazitaxel. [0004] The anticancer compound CX1409 involved in the present invention has a CAS number of 125354-16-7 and a molecular formula of C 45 h 55 NO 15 , molecular weight: 849.92, easily soluble in methanol, its chemical structure is as follo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D305/14A61K31/337A61P35/00
Inventor 姚鹏殷艳松张志强邱俊霞王锡娟
Owner BEIJING KONRUNS PHARM CO LTD